top of page
KELLY
OFFICIAL TITLE: A PHASE II STUDY OF PEMBROLIZUMAB AND ERIBULIN IN PATIENTS WITH HRPOSITIVE/HER2-NEGATIVE METASTATIC BREAST CANCER PREVIOUSLY TREATED WITH ANTHRACYCLINES AND TAXANES.
BLOG ARTICLES RELATED
SCIENTIFIC IMPACT
AACR 2018 – DOWNLOAD THE POSTER
SABCS 2019 – DOWNLOAD THE POSTER
CLINICAL TRIAL DETAILS
THIS A MULTICENTER, OPEN-LABEL, PHASE II CLINICAL TRIAL TO ASSESS THE EFFICACY OF PEMBROLIZUMAB IN COMBINATION WITH ERIBULIN IN FEMALE PATIENTS OLDER THAN 18 YEARS OLD WITH HORMONE RECEPTOR-(HR)POSITIVE/HER2-NEGATIVE METASTATIC BREAST CANCER (MBC) PREVIOUSLY TREATED WITH AT LEAST ONE, BUT NOT MORE THAN TWO, PRIOR CHEMOTHERAPEUTIC REGIMENS FOR TREATMENT OF LOCALLY RECURRENT AND/OR METASTATIC DISEASE. PRIOR THERAPY MUST HAVE INCLUDED AN ANTHRACYCLINE AND A TAXANE. PRIOR ANTI-HORMONAL THERAPY IN THE METASTATIC DISEASE SETTING IS MANDATORY.
THE NUMBER OF PATIENTS TO BE INCLUDED IS 44 PATIENTS AT 11 SITES. ALL ELIGIBLE PATIENTS WILL BE TREATED WITH MK3475 (PEMBROLIZUMAB) 200 MG ON DAY 1 OF EACH 21-DAY CYCLE AND ERIBULIN 1.23 MG/M2 (EQUIVALENT TO ERIBULIN MESYLATE AT 1.4 MG/M2) ON DAYS 1 AND 8 OF EVERY 21-DAY CYCLE.
KELLY AT CLINICALTRIALS.GOV
RESULTS OF THE KELLY STUDY
TUMOR TYPE
PHASE
N
SITES
COUNTRY
STATUS
BREAST
II
44
11
Spain
Closing
KELLY SITES
SPAIN
Hospital Clínico Universitario de Valencia
SPAIN
Instituto Oncológico Baselga - Hospital Quiron Salud Barcelona
SPAIN
Hospital Parc Taulí
SPAIN
Hospital Clínic i Provincial de Barcelona
SPAIN
MD Anderson Cancer Center Madrid
SPAIN
Hospital Universitario Ramón y Cajal
SPAIN
Complejo Hospitalario de Navarra
SPAIN
Complejo Hospitalario Universitario A Coruña (CHUAC)
SPAIN
Hospital Universitario Virgen del Rocío
SPAIN
Hospital Clínico Universitario Virgen de la Arrixaca
SPAIN
Hospital Arnau de Vilanova de Valencia
bottom of page